Fig 1: (A) RNASET2, phAKT, phmTOR, and Mcl-1 protein levels as determined by Western blotting in DCs exposed to hypoxia for 24 h and treated or untreated in the last 6 h with Wortmannin. (B) phAKT, phmTOR, and Mcl-1 protein levels as determined by Western blotting in DCs exposed to hypoxia for 24 h in the presence or not of LPS. (C) RNASET2, mRNA, and protein levels as determined by RT-qPCR analysis and Western blotting, respectively, in DCs exposed to hypoxia in the presence or not in the presence of LPS for 24 h. RNASET2 protein levels as determined by Western blot analysis in DCs exposed to hypoxia in the presence of LPS for 24 h and treated or untreated in the last 6 h with Wortmannin. All blots shown are representative of at least three independent experiments and ß-actin was used as loading control. ß-actin was used as a housekeeping gene for RT-qPCR analysis. * indicates statistically significant differences (p = 0.05; n = 3).
Fig 2: (A) HIF-1a and STAT3a protein levels as determined by Western blotting and BNIP3; VEGF-A and CXCR4 mRNAs as determined by RT-qPCR analysis after 24 h exposure to normoxia and hypoxia. (B) RNASET2 mRNA after 24 and 48 h exposure to normoxia and hypoxia as determined by RT-qPCR, RNASET2 protein levels, as detected by Western Blotting (after 24 h), and secretion as measured by ELISA assay (after 48 h). (C) Live cell percentage after 48 h exposure to normoxia and hypoxia, as determined by LIVE/DEAD assay, phAKT, phmTOR, and Mcl-1 protein levels after 24 h exposure to normoxia and hypoxia, as determined by Western blotting. All blots shown are representative of at least three independent experiments and ß-actin was used as loading control. ß-actin was used as a housekeeping gene for RT-qPCR analysis. * indicates statistically significant differences (p = 0.05; n = 3).
Supplier Page from Biomatik for Human Ribonuclease T2 (RNASET2) ELISA Kit